Real World Outcomes of Combined MSC Therapy and Functional Medicine in Autism: Early Functional and Behavioral Improvements

Background: Stem cell–based therapy has gained increasing attention as a regenerative approach for neurodevelopmental and functional disorders. While global research supports the therapeutic potential of mesenchymal stem cells (MSCs), early clinical outcomes remain variable, and American cohort data are limited. This hybrid clinical‑trial study integrates empirical findings from 34 U.S. patients with a mechanistic scientific review to evaluate early functional and behavioral outcomes following MSC therapy. Methods: Thirty‑four patients aged 4–30 years received MSC therapy using standardized cell quantities (15M, 50M, 100M) and four dosing intensities (Dose 1–4). Clinical outcomes were assessed across eight domains: digestion, toilet habits, sleep, hyperactivity, speech, communication, appetite, and overall improvement. Descriptive statistics, dose–response comparisons, and age‑group analyses were performed. Mechanistic interpretation was integrated using established MSC literature. Results: Functional improvements appeared earlier and more frequently than developmental outcomes. Toilet habits improved in of patients, followed by hyperactivity reduction , digestion , and sleep . Speech and communication improved in each. Dose 3 demonstrated the highest improvement rate , and younger patients showed significantly greater responsiveness than adolescents or adults. Half the cohort exhibited no early improvement, consistent with expected MSC timelines. Conclusion: Early findings suggest that MSC therapy may yield meaningful functional improvements in younger American patients, particularly at moderate‑to‑high dosing levels. The integration of empirical data with mechanistic insights highlights the therapeutic potential of MSCs while emphasizing the need for larger controlled studies in the United States. These findings should be interpreted cautiously due to the small sample size and early follow‑up window.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-12-31
DOI
https://doi.org/10.5281/zenodo.18336325
Primary Topic
Mesenchymal stem cell research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real World Outcomes of Combined MSC Therapy and Functional Medicine in Autism: Early Functional and Behavioral Improvements

Abdullah Al Noman, Syeda Shayan Zehra, M. Mojibul Haque
Zenodo (CERN European Organization for Nuclear Research)
Mesenchymal stem cell research
article

Real World Outcomes of Combined MSC Therapy and Functional Medicine in Autism: Early Functional and Behavioral Improvements

Abdullah Al Noman, Syeda Shayan Zehra, M. Mojibul Haque
article en

Abstract

Background: Stem cell–based therapy has gained increasing attention as a regenerative approach for neurodevelopmental and functional disorders. While global research supports the therapeutic potential of mesenchymal stem cells (MSCs), early clinical outcomes remain variable, and American cohort data are limited. This hybrid clinical‑trial study integrates empirical findings from 34 U.S. patients with a mechanistic scientific review to evaluate early functional and behavioral outcomes following MSC therapy. Methods: Thirty‑four patients aged 4–30 years received MSC therapy using standardized cell quantities (15M, 50M, 100M) and four dosing intensities (Dose 1–4). Clinical outcomes were assessed across eight domains: digestion, toilet habits, sleep, hyperactivity, speech, communication, appetite, and overall improvement. Descriptive statistics, dose–response comparisons, and age‑group analyses were performed. Mechanistic interpretation was integrated using established MSC literature. Results: Functional improvements appeared earlier and more frequently than developmental outcomes. Toilet habits improved in of patients, followed by hyperactivity reduction , digestion , and sleep . Speech and communication improved in each. Dose 3 demonstrated the highest improvement rate , and younger patients showed significantly greater responsiveness than adolescents or adults. Half the cohort exhibited no early improvement, consistent with expected MSC timelines. Conclusion: Early findings suggest that MSC therapy may yield meaningful functional improvements in younger American patients, particularly at moderate‑to‑high dosing levels. The integration of empirical data with mechanistic insights highlights the therapeutic potential of MSCs while emphasizing the need for larger controlled studies in the United States. These findings should be interpreted cautiously due to the small sample size and early follow‑up window.

Zenodo (CERN European Organization for Nuclear Research)
American International University-Bangladesh (BD), Integrative Medicine Institute (US), American Institute of Bangladesh Studies (BD)
Openalex Percentile: Top 24%
Mesenchymal stem cell research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.